Last year, several cases were identified in American patients traveling to Mexico to receive cosmetic surgery. The source of transmission was discovered, and one of the investigators, Sarah Bergbower DCLS, MS, MLS (ASCP)CM, discusses her part with 1 of the cases.
The Xpert HCV assay facilitates rapid HCV diagnosis in nonclinical settings, aiding high-risk populations like those under community supervision.
This week, recent investigations link contaminated ice machines to Burkholderia multivorans infections, the hepatitis treatment market is projected to grow to USD 30.2 billion by 2032, 2020 guidelines recommend targeting specific AUC levels for optimizing vancomycin therapy, and more
In our latest roundtable series, the discussion addressed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.
A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.
Despite evidence of their effectiveness in reducing hospitalization and mortality rates, many older individuals remain untreated, with recent studies highlighting significant disparities in treatment access and adherence.
A holistic, multifaceted approach with a variety of stakeholders are needed to address antimicrobial resistance (AMR). The recent UN meeting on this topic looked to bring together government leaders, industry, and public health officials to discuss strategies regarding the global health crisis.
A new study finds that 1.4 million people aged 12-59 with current hepatitis C (HCV) infection, including over a third of them without a history of injection drug use.
The ideal parameter for vancomycin monitoring is the area under the curve, which can be calculated using pharmacokinetic equations or Bayesian software.
The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus-related lower respiratory tract disease in older adults over three seasons.
Over the past four years, an investigation across California hospitals has linked ice and water use in clinical settings to potential infections.
The global hepatitis treatment market is more than a financial figure; it is a key area in the effort to combat the silent disease that impacts millions around the world.
The pharmaceutical industry faces challenges when investing in new antibiotics, which emphasizes the need for regulatory reforms, incentives, and collaborative efforts between government, healthcare organizations, and private companies. The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies.
People can now take the Healgen Rapid Check COVID-19/Flu A&B Antigen Test in their homes without a prescription.
More food recalls, including eggs, guacamole, Sriracha, and vegetables, were issued due to health risks from contamination, prompting consumer action nationwide.
Basilea Pharmaceutica says its investigational therapy, fosmanogepix, is being studied for candidemia and invasive candidiasis.
Some FDA recalls announced this past week involve various food products, such as veggie straws and sprouts, prompting consumers to remain aware of potential health risks.
Forty percent of the dose of the PCV 13 vaccine, but not of the PCV 10 or lower dose, was found noninferior to full doses when immunizing infants in Kenya.
Healthcare workers receiving additional COVID-19 vaccine doses had fewer ongoing symptoms, a new test differentiates bacterial from viral infections, CDC reports 10 deaths linked to ongoing listeria outbreak, and more this week from Contagion.
The pharmaceutical company said there were no safety issues associated with the decision.
Moderna has begun its study examining its investigational norovirus vaccine, mRNA-1403, to determine its efficacy, safety and immunogenicity.
Carter Keller discusses the company's recent $135.2 million contract with BARDA to develop recombinant polyclonal antibody therapies targeting botulinum neurotoxins and an unspecified biothreat, highlighting their innovative approach to address emerging health threats.
In the second installment of a 2-part series on this form of guided therapy, the lead investigator describes findings and the potential of biomarkers in antibiotic stewardship.
Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.
Part 1 of James F Cummings, MD interview, discusses the trial's goals and highlights the vaccine's potential to generate mucosal immunity, its logistical advantages and ease of administration.
In part 1 of a 2-part story, an investigator discusses the use of procalcitonin and C-reactive protein guided protocols for community-acquired pneumonia (CAP).
This study highlights fidaxomicin’s advantages over vancomycin, including lower recurrence rates of CDI and higher sustained clinical responses.
Enanta Pharmaceuticals says its investigational therapy, EDP-323, was found to be safe and efficacious against the respiratory virus.
Stool antigen testing added to fecal immunochemical testing for colorectal cancer screening resulted in higher participation rates, yet showed no significant differences in gastric cancer incidence or mortality.
Jennifer Quinn, head of Global Value & Access, Debiopharm, offers insights on pull incentives and how they look to get more antibiotics to market.
